CN113227057A - 化合物及其用于治疗α1-抗胰蛋白酶缺乏症的用途 - Google Patents
化合物及其用于治疗α1-抗胰蛋白酶缺乏症的用途 Download PDFInfo
- Publication number
- CN113227057A CN113227057A CN201980082707.2A CN201980082707A CN113227057A CN 113227057 A CN113227057 A CN 113227057A CN 201980082707 A CN201980082707 A CN 201980082707A CN 113227057 A CN113227057 A CN 113227057A
- Authority
- CN
- China
- Prior art keywords
- methyl
- a1at
- benzamide
- oxopyrimidin
- dimethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 33
- 150000001875 compounds Chemical class 0.000 title claims description 57
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 title abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 155
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 claims description 118
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 claims description 108
- -1 (6-oxopyrimidin-1 (6H) -yl) methyl Chemical group 0.000 claims description 83
- 229910052757 nitrogen Inorganic materials 0.000 claims description 61
- 230000028327 secretion Effects 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 17
- 238000000338 in vitro Methods 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 4
- 239000000411 inducer Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000002753 trypsin inhibitor Substances 0.000 abstract description 10
- 239000013078 crystal Substances 0.000 abstract description 3
- 230000007812 deficiency Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 45
- 241000282414 Homo sapiens Species 0.000 description 40
- 241000699670 Mus sp. Species 0.000 description 23
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 23
- 229960000237 vorinostat Drugs 0.000 description 23
- 230000000694 effects Effects 0.000 description 20
- 238000002965 ELISA Methods 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 239000003981 vehicle Substances 0.000 description 15
- 238000011534 incubation Methods 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 14
- 238000003556 assay Methods 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 210000003494 hepatocyte Anatomy 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 229920001213 Polysorbate 20 Polymers 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 231100000673 dose–response relationship Toxicity 0.000 description 8
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 8
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 7
- 102000004142 Trypsin Human genes 0.000 description 7
- 108090000631 Trypsin Proteins 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000012588 trypsin Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 238000006116 polymerization reaction Methods 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 239000012679 serum free medium Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 238000003305 oral gavage Methods 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000012470 diluted sample Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000012089 stop solution Substances 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- IRHCCBFRTYXLNZ-UHFFFAOYSA-N 4-[(6-oxopyrimidin-1-yl)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CN1C(=O)C=CN=C1 IRHCCBFRTYXLNZ-UHFFFAOYSA-N 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 102000012479 Serine Proteases Human genes 0.000 description 3
- 108010022999 Serine Proteases Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000010811 Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Methods 0.000 description 3
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 3
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 2
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 2
- 101710081722 Antitrypsin Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 108010028275 Leukocyte Elastase Proteins 0.000 description 2
- 102000016799 Leukocyte elastase Human genes 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001475 anti-trypsic effect Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical class OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- OLHGFZZEOLMPSI-UHFFFAOYSA-N 4-(bromomethyl)-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=C(CBr)C=C1 OLHGFZZEOLMPSI-UHFFFAOYSA-N 0.000 description 1
- SBYQPEKNMQWJQO-UHFFFAOYSA-N 8-anilino-5-(4-anilino-5-sulfonaphthalen-1-yl)naphthalene-1-sulfonic acid Chemical compound C=12C(S(=O)(=O)O)=CC=CC2=C(C=2C3=CC=CC(=C3C(NC=3C=CC=CC=3)=CC=2)S(O)(=O)=O)C=CC=1NC1=CC=CC=C1 SBYQPEKNMQWJQO-UHFFFAOYSA-N 0.000 description 1
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- IWORMWOSTFKLJS-UHFFFAOYSA-N N-(4-hydroxy-3,5-dimethylphenyl)-2,5-dimethyl-3-thiophenesulfonamide Chemical compound S1C(C)=CC(S(=O)(=O)NC=2C=C(C)C(O)=C(C)C=2)=C1C IWORMWOSTFKLJS-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- PJTFOTDTWDPHNM-UHFFFAOYSA-N NC(NC1=[S+]CC(C=C2)=CC=C2[N+]([O-])=O)=NC2=C1NC=N2 Chemical compound NC(NC1=[S+]CC(C=C2)=CC=C2[N+]([O-])=O)=NC2=C1NC=N2 PJTFOTDTWDPHNM-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000012404 Orosomucoid Human genes 0.000 description 1
- 108010061952 Orosomucoid Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 229940122055 Serine protease inhibitor Drugs 0.000 description 1
- 101710102218 Serine protease inhibitor Proteins 0.000 description 1
- 101150069374 Serpina1 gene Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000002603 aneugenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 231100000244 chromosomal damage Toxicity 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- VWLWTJHKQHRTNC-UHFFFAOYSA-L dipotassium;8-anilino-5-(4-anilino-5-sulfonatonaphthalen-1-yl)naphthalene-1-sulfonate Chemical compound [K+].[K+].C=12C(S(=O)(=O)[O-])=CC=CC2=C(C=2C3=CC=CC(=C3C(NC=3C=CC=CC=3)=CC=2)S([O-])(=O)=O)C=CC=1NC1=CC=CC=C1 VWLWTJHKQHRTNC-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940035482 glassia Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 102000051631 human SERPINA1 Human genes 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical class OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000018448 secretion by cell Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- GSIBTIUXYYFCPU-UHFFFAOYSA-N tert-butyl 4-(bromomethyl)benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=C(CBr)C=C1 GSIBTIUXYYFCPU-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 101150005573 uvrA gene Proteins 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229940032528 zemaira Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (13)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1820450.3A GB201820450D0 (en) | 2018-12-14 | 2018-12-14 | Compound and its use for the treatment of alpha1-antitryspin deficiency |
GB1820450.3 | 2018-12-14 | ||
PCT/GB2019/053552 WO2020120992A1 (en) | 2018-12-14 | 2019-12-13 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113227057A true CN113227057A (zh) | 2021-08-06 |
Family
ID=65147137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980082707.2A Pending CN113227057A (zh) | 2018-12-14 | 2019-12-13 | 化合物及其用于治疗α1-抗胰蛋白酶缺乏症的用途 |
Country Status (21)
Country | Link |
---|---|
US (2) | US11312689B2 (zh) |
EP (1) | EP3894393B8 (zh) |
JP (1) | JP7487203B2 (zh) |
KR (1) | KR20210104080A (zh) |
CN (1) | CN113227057A (zh) |
AU (1) | AU2019398520A1 (zh) |
BR (1) | BR112021011477A2 (zh) |
CA (1) | CA3122658A1 (zh) |
CO (1) | CO2021009083A2 (zh) |
CR (1) | CR20210376A (zh) |
EA (1) | EA202191239A1 (zh) |
EC (1) | ECSP21051825A (zh) |
GB (1) | GB201820450D0 (zh) |
IL (1) | IL283938A (zh) |
MA (1) | MA54456A (zh) |
MX (1) | MX2021006884A (zh) |
NI (1) | NI202100047A (zh) |
PE (1) | PE20211789A1 (zh) |
SG (1) | SG11202105878WA (zh) |
WO (1) | WO2020120992A1 (zh) |
ZA (1) | ZA202103977B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201820450D0 (en) | 2018-12-14 | 2019-01-30 | Z Factor Ltd | Compound and its use for the treatment of alpha1-antitryspin deficiency |
GB201918404D0 (en) * | 2019-12-13 | 2020-01-29 | Z Factor Ltd | Compounds and their use for the treatment of aplha1-antitrypsin deficiency |
GB202009074D0 (en) * | 2020-06-15 | 2020-07-29 | Z Factor Ltd | Compound |
GB202009069D0 (en) * | 2020-06-15 | 2020-07-29 | Z Factor Ltd | Process |
GB202108544D0 (en) * | 2021-06-15 | 2021-07-28 | Z Factor Ltd | Compounds and their use for the treatment of alpha1-antitrypsin deficiency |
GB202108542D0 (en) * | 2021-06-15 | 2021-07-28 | Z Factor Ltd | Compounds and their use for the treatment of alpha1-antitrypsin deficiency |
GB202108543D0 (en) * | 2021-06-15 | 2021-07-28 | Z Factor Ltd | Compounds and their use for the treatment of alpha1-antitrypsin deficiency |
WO2022263829A1 (en) * | 2021-06-16 | 2022-12-22 | Z Factor Limited | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000052034A2 (en) * | 1999-03-05 | 2000-09-08 | The Trustees Of University Technology Corporation | Inhibitors of serine protease activity, methods and compositions for treatment of viral infections |
WO2001052830A2 (en) * | 2000-01-20 | 2001-07-26 | Washington University | METHODS TO TREAT α-1-ANTITRYPSIN DEFICIENCY |
WO2005092899A1 (en) * | 2004-03-26 | 2005-10-06 | Methylgene Inc. | Inhibitors of histone deacetylase |
US20070167621A1 (en) * | 2003-04-03 | 2007-07-19 | Pharmacia Corporation | Substituted pyrimidinones |
EP1832586A1 (en) * | 2006-03-10 | 2007-09-12 | Oridis Biomed Forschungs- und Entwicklungs GmbH | Thiazole-piperidine derivatives in treatment of diseases of liver and the pancreas |
WO2008143633A2 (en) * | 2007-01-10 | 2008-11-27 | University Of Florida | Compounds and methods for treatment of alpha-1 antitrypsin deficiency |
CN101406473A (zh) * | 2007-10-12 | 2009-04-15 | 中国科学院上海有机化学研究所 | 二氢嘧啶化合物的用途及含其的药物组合物 |
WO2013070657A1 (en) * | 2011-11-08 | 2013-05-16 | Arena Pharmaceuticals, Inc. | Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto |
WO2013068909A1 (en) * | 2011-11-11 | 2013-05-16 | Pfizer Inc. | N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia |
US20150045344A1 (en) * | 2007-12-20 | 2015-02-12 | Bayer Intellectual Property Gmbh | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof |
WO2016031987A1 (ja) * | 2014-08-29 | 2016-03-03 | 国立大学法人東京大学 | オートタキシン阻害活性を有するピリミジノン誘導体 |
US20160340319A1 (en) * | 2013-02-06 | 2016-11-24 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
WO2021116706A1 (en) * | 2019-12-13 | 2021-06-17 | Z Factor Limited | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY |
WO2021116707A1 (en) * | 2019-12-13 | 2021-06-17 | Z Factor Limited | 4-((2-oxopyri din-1 (2h)-yl)methyl)benzamides for treating alpha1 -antitrypsin deficiency |
WO2021116709A1 (en) * | 2019-12-13 | 2021-06-17 | Z Factor Limited | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY |
WO2021255429A1 (en) * | 2020-06-15 | 2021-12-23 | Z Factor Limited | Process for preparing n,n-dimethyl-4-((6-oxopyrimidin-1(6h)-yl)methyl)benzamide from 4-((6-oxopyrimidin-1(6h)-yl)methyl)benzoic acid, and crystalline forms of the benzamide |
WO2022263829A1 (en) * | 2021-06-16 | 2022-12-22 | Z Factor Limited | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY |
GB2612007A (en) * | 2021-06-15 | 2023-04-26 | Z Factor Ltd | Compounds |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7183287B2 (en) * | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
GB201820450D0 (en) * | 2018-12-14 | 2019-01-30 | Z Factor Ltd | Compound and its use for the treatment of alpha1-antitryspin deficiency |
-
2018
- 2018-12-14 GB GBGB1820450.3A patent/GB201820450D0/en not_active Ceased
-
2019
- 2019-12-13 MA MA054456A patent/MA54456A/fr unknown
- 2019-12-13 SG SG11202105878WA patent/SG11202105878WA/en unknown
- 2019-12-13 JP JP2021534304A patent/JP7487203B2/ja active Active
- 2019-12-13 BR BR112021011477-7A patent/BR112021011477A2/pt unknown
- 2019-12-13 AU AU2019398520A patent/AU2019398520A1/en active Pending
- 2019-12-13 KR KR1020217021705A patent/KR20210104080A/ko unknown
- 2019-12-13 WO PCT/GB2019/053552 patent/WO2020120992A1/en active Application Filing
- 2019-12-13 CR CR20210376A patent/CR20210376A/es unknown
- 2019-12-13 CN CN201980082707.2A patent/CN113227057A/zh active Pending
- 2019-12-13 PE PE2021000872A patent/PE20211789A1/es unknown
- 2019-12-13 EP EP19835312.0A patent/EP3894393B8/en active Active
- 2019-12-13 CA CA3122658A patent/CA3122658A1/en active Pending
- 2019-12-13 EA EA202191239A patent/EA202191239A1/ru unknown
- 2019-12-13 MX MX2021006884A patent/MX2021006884A/es unknown
-
2021
- 2021-06-09 ZA ZA2021/03977A patent/ZA202103977B/en unknown
- 2021-06-11 NI NI202100047A patent/NI202100047A/es unknown
- 2021-06-11 US US17/345,928 patent/US11312689B2/en active Active
- 2021-06-13 IL IL283938A patent/IL283938A/en unknown
- 2021-07-12 CO CONC2021/0009083A patent/CO2021009083A2/es unknown
- 2021-07-13 EC ECSENADI202151825A patent/ECSP21051825A/es unknown
-
2022
- 2022-03-21 US US17/699,408 patent/US20220274932A1/en active Pending
Patent Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000052034A2 (en) * | 1999-03-05 | 2000-09-08 | The Trustees Of University Technology Corporation | Inhibitors of serine protease activity, methods and compositions for treatment of viral infections |
WO2001052830A2 (en) * | 2000-01-20 | 2001-07-26 | Washington University | METHODS TO TREAT α-1-ANTITRYPSIN DEFICIENCY |
US20020006909A1 (en) * | 2000-01-20 | 2002-01-17 | Perlmutter David H. | Methods to treat alpha1-antitrypsin deficiency |
US20070167621A1 (en) * | 2003-04-03 | 2007-07-19 | Pharmacia Corporation | Substituted pyrimidinones |
WO2005092899A1 (en) * | 2004-03-26 | 2005-10-06 | Methylgene Inc. | Inhibitors of histone deacetylase |
JP2007530459A (ja) * | 2004-03-26 | 2007-11-01 | メシルジーン、インコーポレイテッド | ヒストンデアセチラーゼの阻害剤 |
EP1832586A1 (en) * | 2006-03-10 | 2007-09-12 | Oridis Biomed Forschungs- und Entwicklungs GmbH | Thiazole-piperidine derivatives in treatment of diseases of liver and the pancreas |
WO2008143633A2 (en) * | 2007-01-10 | 2008-11-27 | University Of Florida | Compounds and methods for treatment of alpha-1 antitrypsin deficiency |
CN101406473A (zh) * | 2007-10-12 | 2009-04-15 | 中国科学院上海有机化学研究所 | 二氢嘧啶化合物的用途及含其的药物组合物 |
US20150045344A1 (en) * | 2007-12-20 | 2015-02-12 | Bayer Intellectual Property Gmbh | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof |
WO2013070657A1 (en) * | 2011-11-08 | 2013-05-16 | Arena Pharmaceuticals, Inc. | Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto |
WO2013068909A1 (en) * | 2011-11-11 | 2013-05-16 | Pfizer Inc. | N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia |
US20160340319A1 (en) * | 2013-02-06 | 2016-11-24 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
WO2016031987A1 (ja) * | 2014-08-29 | 2016-03-03 | 国立大学法人東京大学 | オートタキシン阻害活性を有するピリミジノン誘導体 |
WO2021116706A1 (en) * | 2019-12-13 | 2021-06-17 | Z Factor Limited | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY |
WO2021116707A1 (en) * | 2019-12-13 | 2021-06-17 | Z Factor Limited | 4-((2-oxopyri din-1 (2h)-yl)methyl)benzamides for treating alpha1 -antitrypsin deficiency |
WO2021116709A1 (en) * | 2019-12-13 | 2021-06-17 | Z Factor Limited | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY |
CN115023416A (zh) * | 2019-12-13 | 2022-09-06 | Z因子有限公司 | 用于治疗α1-抗胰蛋白酶缺乏症的4-((2-氧代吡啶-1(2H)-基)甲基)苯甲酰胺 |
WO2021255429A1 (en) * | 2020-06-15 | 2021-12-23 | Z Factor Limited | Process for preparing n,n-dimethyl-4-((6-oxopyrimidin-1(6h)-yl)methyl)benzamide from 4-((6-oxopyrimidin-1(6h)-yl)methyl)benzoic acid, and crystalline forms of the benzamide |
GB2612007A (en) * | 2021-06-15 | 2023-04-26 | Z Factor Ltd | Compounds |
WO2022263829A1 (en) * | 2021-06-16 | 2022-12-22 | Z Factor Limited | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY |
Non-Patent Citations (3)
Title |
---|
MARION BOUCHECAREILH等: "Histone Deacetylase Inhibitor (HDACi) Suberoylanilide Hydroxamic Acid (SAHA)-mediated Correction of ɑ1-Antitrypsin Deficiency", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 287, no. 45, 2 November 2012 (2012-11-02), pages 38265, XP055667908, DOI: 10.1074/jbc.M112.404707 * |
MEERA MALLYA 等: "Small Molecules Block the Polymerization of Z ɑ1 -Antitrypsin and Increase the Clearance of Intracellular Aggregates", JOURNAL OF MEDICINAL CHEMISTRY, vol. 50, no. 22, 5 October 2007 (2007-10-05), pages 5357, XP055667904, DOI: 10.1021/jm070687z * |
郭玉婷;蒋琳;: "α1-抗胰蛋白酶的缺乏与治疗", 微生物学免疫学进展, vol. 43, no. 03, 30 June 2015 (2015-06-30), pages 72 - 75 * |
Also Published As
Publication number | Publication date |
---|---|
KR20210104080A (ko) | 2021-08-24 |
JP2022515372A (ja) | 2022-02-18 |
CR20210376A (es) | 2021-10-18 |
BR112021011477A2 (pt) | 2021-08-31 |
EP3894393B8 (en) | 2023-02-15 |
US20220274932A1 (en) | 2022-09-01 |
IL283938A (en) | 2021-07-29 |
ZA202103977B (en) | 2022-10-26 |
SG11202105878WA (en) | 2021-07-29 |
AU2019398520A1 (en) | 2021-07-01 |
JP7487203B2 (ja) | 2024-05-20 |
EA202191239A1 (ru) | 2021-09-21 |
NI202100047A (es) | 2021-08-31 |
CO2021009083A2 (es) | 2021-07-30 |
CA3122658A1 (en) | 2020-06-18 |
GB201820450D0 (en) | 2019-01-30 |
ECSP21051825A (es) | 2021-11-18 |
EP3894393B1 (en) | 2022-12-21 |
US20210332015A1 (en) | 2021-10-28 |
EP3894393A1 (en) | 2021-10-20 |
WO2020120992A1 (en) | 2020-06-18 |
US11312689B2 (en) | 2022-04-26 |
PE20211789A1 (es) | 2021-09-09 |
MA54456A (fr) | 2022-03-23 |
MX2021006884A (es) | 2021-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113227057A (zh) | 化合物及其用于治疗α1-抗胰蛋白酶缺乏症的用途 | |
JP2019503362A (ja) | Dubの阻害剤としてのシアノピロリジン誘導体 | |
EP2102192B1 (en) | Solid state forms of racemic ilaprazole | |
CN115003658B (zh) | 化合物及其用于治疗α1-抗胰蛋白酶缺乏症的用途 | |
CN115023416B (zh) | 用于治疗α1-抗胰蛋白酶缺乏症的4-((2-氧代吡啶-1(2H)-基)甲基)苯甲酰胺 | |
CN115003381B (zh) | 化合物及其用于治疗α1-抗胰蛋白酶缺乏症的用途 | |
CN115003380B (zh) | 化合物及其用于治疗α1-抗胰蛋白酶缺乏症的用途 | |
CN114206441B (zh) | Drp1-细丝蛋白复合物形成抑制剂 | |
JP2023529570A (ja) | Usp30阻害剤としての活性を有するn-シアノピロリジン | |
US20240197707A1 (en) | Compositions and their Use for the Treatment of A1-Antitrypsin Deficiency | |
US20180116981A1 (en) | Non-peptidic gapdh aggregation inhibitor | |
CN115003669A (zh) | 化合物及其用于治疗α1-抗胰蛋白酶缺乏症的用途 | |
CN115716829A (zh) | 一种喹啉并咪唑酮联氘代吡唑类化合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: Cheshire Applicant after: Z factor Co.,Ltd. Address before: Cambridge County, England Applicant before: Z factor Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240207 Address after: Cheshire Applicant after: Sentesa Pharmaceuticals (UK) Ltd. Country or region after: United Kingdom Address before: Cheshire Applicant before: Z factor Co.,Ltd. Country or region before: United Kingdom |